Vertex pays Entrada $224M for preclinical rare disease drug, opening new front in assault on dystrophy

Vertex has opened another front in its attempt to treat a rare cause of muscle weakness, paying Entrada Therapeutics $224 million upfront for the preclinical prospect ENTR-701.